Amgen (AMGN), Thursday said that Phase 3 DESCARTES (Durable Effect of PCSK9 Antibody Compared with Placebo Study) trial evaluating the long-term 52-week safety and efficacy of evolocumab for the treatment of high cholesterol met its primary endpoint of percent reduction from baseline in low-density lipoprotein cholesterol.
The mean percent reduction in LDL-C, or 'bad' cholesterol, was consistent with the results observed in the 52-week analysis of the Phase 2 OSLER (Open Label Study of Long Term Evaluation Against LDL-C) study. The DESCARTES trial evaluated safety, tolerability and efficacy in 901 patients with high LDL-C and a range of cardiovascular risk.
Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove LDL-C from the blood.
"These data contribute to the growing body of research suggesting that evolocumab may offer a new treatment option for patients with dyslipidemia." said Sean Harper, executive vice president of Research and Development of the company.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.